Authors:
Anderson, CP
Seeger, RC
Satake, N
Monforte-Munoz, HL
Keshelava, N
Bailey, HH
Reynolds, CP
Citation: Cp. Anderson et al., Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line, J PED H ONC, 23(8), 2001, pp. 500-505
Citation: Cp. Reynolds et Rc. Seeger, Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma, J PED H ONC, 23(3), 2001, pp. 150-152
Authors:
White, PS
Thompson, PM
Seifried, BA
Sulman, EP
Jensen, SJ
Guo, C
Maris, JM
Hogarty, MD
Allen, C
Biegel, JA
Matise, TC
Gregory, SG
Reynolds, CP
Brodeur, GM
Citation: Ps. White et al., Detailed molecular analysis of 1p36 in neuroblastoma, MED PED ONC, 36(1), 2001, pp. 37-41
Citation: Pm. Thompson et al., Homozygous deletion of CDKN2A (p16(INK4a)/p14(ARF)) but not within 1p36 orat other tumor suppressor loci in neuroblastoma, CANCER RES, 61(2), 2001, pp. 679-686
Authors:
Keshelava, N
Zuo, JJ
Chen, P
Waidyaratne, SN
Luna, MC
Gomer, CJ
Triche, TJ
Reynolds, CP
Citation: N. Keshelava et al., Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines', CANCER RES, 61(16), 2001, pp. 6185-6193
Authors:
Wang, HT
Maurer, DJ
Reynolds, CP
Cabot, MC
Citation: Ht. Wang et al., N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase, CANCER RES, 61(13), 2001, pp. 5102-5105
Authors:
Hoon, DSB
Kuo, CT
Wen, SH
Wang, H
Metelitsa, L
Reynolds, CP
Seeger, RC
Citation: Dsb. Hoon et al., Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow, AM J PATH, 159(2), 2001, pp. 493-500
Authors:
Maurer, BJ
Melton, L
Billups, C
Cabot, MC
Reynolds, CP
Citation: Bj. Maurer et al., Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism, J NAT CANC, 92(23), 2000, pp. 1897-1909
Citation: Yl. Wang et al., Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors, CLIN CANC R, 6(2), 2000, pp. 551-558
Authors:
Seeger, RC
Reynolds, CP
Gallego, R
Stram, DO
Gerbing, RB
Matthay, KK
Citation: Rc. Seeger et al., Quantitative tumor cell content of bone marrow and blood as a predictor ofoutcome in stage IV neuroblastoma: A Children's Cancer Group Study, J CL ONCOL, 18(24), 2000, pp. 4067-4076
Citation: Rl. Chen et al., Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating, CANCER IMMU, 48(11), 2000, pp. 603-612
Citation: N. Keshelava et al., p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma, MED PED ONC, 35(6), 2000, pp. 563-568
Authors:
Reynolds, CP
Wang, Y
Melton, LJ
Einhorn, PA
Slamon, DJ
Maurer, BJ
Citation: Cp. Reynolds et al., Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide, MED PED ONC, 35(6), 2000, pp. 597-602
Authors:
Goto, H
Keshelava, N
Matthay, KK
Lukens, JN
Gerbing, RB
Stram, DO
Seeger, RC
Reynolds, CP
Citation: H. Goto et al., Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors, MED PED ONC, 35(6), 2000, pp. 619-622
Authors:
Choi, LMR
Kim, NW
Zuo, JJ
Gerbing, R
Stram, D
Lukens, JN
Matthay, KK
Seeger, RC
Reynolds, CP
Citation: Lmr. Choi et al., Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma, MED PED ONC, 35(6), 2000, pp. 647-650
Authors:
Anderson, CP
Keshelava, N
Satake, N
Meek, WH
Reynolds, CP
Citation: Cp. Anderson et al., Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression, MED PED ONC, 35(6), 2000, pp. 659-662
Citation: Kk. Matthay et Cp. Reynolds, Is there a role for retinoids to treat minimal residual disease in neuroblastoma?, BR J CANC, 83(9), 2000, pp. 1121-1123
Authors:
Maurer, BJ
Metelitsa, LS
Seeger, RC
Cabot, MC
Reynolds, CP
Citation: Bj. Maurer et al., Increase of ceramide and induction of mixed apoptosis necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines, J NAT CANC, 91(13), 1999, pp. 1138-1146
Authors:
Matthay, KK
Villablanca, JG
Seeger, RC
Stram, DO
Harris, RE
Ramsay, NK
Swift, P
Shimada, H
Black, CT
Brodeur, GM
Gerbing, RB
Reynolds, CP
Citation: Kk. Matthay et al., Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid, N ENG J MED, 341(16), 1999, pp. 1165-1173
Authors:
Wang, B
Feng, L
Hu, Y
Huang, SH
Reynolds, CP
Wu, LT
Jong, AY
Citation: B. Wang et al., The essential role of Saccharomyces cerevisiae CDC6 nucleotide-binding site in cell growth, DNA synthesis, and Orc1 association, J BIOL CHEM, 274(12), 1999, pp. 8291-8298
Authors:
Anderson, CP
Tsai, JM
Meek, WE
Liu, RM
Tang, YM
Forman, HJ
Reynolds, CP
Citation: Cp. Anderson et al., Depletion of glutathione by buthionine sulfoximine is cytotoxic for human neuroblastoma cell lines via apoptosis, EXP CELL RE, 246(1), 1999, pp. 183-192
Authors:
Keshelava, N
Seeger, RC
Groshen, S
Reynolds, CP
Citation: N. Keshelava et al., Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy, CANCER RES, 58(23), 1998, pp. 5396-5405